within Pharmacolibrary.Drugs.ATC.J;

model J06BB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.003,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Hepatitis B immunoglobulin (HBIG) is a human immune globulin containing a high titer of antibodies against hepatitis B virus (HBV). It is used for post-exposure prophylaxis to prevent hepatitis B infection, especially in individuals exposed to HBV (such as after perinatal exposure, needle stick injuries, or sexual exposure), and in combination with hepatitis B vaccine to prevent reinfection following liver transplantation. HBIG is approved and in current clinical use worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameter estimates primarily from healthy adult volunteers after intramuscular administration; in clinical use, parameters may vary depending on individual factors.</p><h4>References</h4><ol><li>Shin Hwang, Gi Won Song, Young Kyu Chung, Chul Soo Ahn, Ki Hun Kim, Deok Bog Moon, Tae Yong Ha, Dong Hwan Jung, Gil Chun Park, Young In Yoon, Hwui Dong Cho, Jae Hyun Kwon, Sang Hyun Kang, I Ji Jeong, Jin Uk Choi, Sung Gyu Lee,Determination of Hepatitis B Immunoglobulin Infusion Interval Using Pharmacokinetic Half-life Simulation for Posttransplant Hepatitis B Prophylaxis.,Journal of Korean medical science,2019<a href='https://pubmed.ncbi.nlm.nih.gov/31583871/'>https://pubmed.ncbi.nlm.nih.gov/31583871/</a></li><li>Rika A Furuta, Teruhito Yasui, Takeharu Minamitani, Hiroki Akiba, Chizu Toyoda, Ryutaro Tobita, Kazuta Yasui, Ryota Aminaka, Mikako Masaki, Masahiro Satake,Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study.,Transfusion,2023<a href='https://pubmed.ncbi.nlm.nih.gov/37119513/'>https://pubmed.ncbi.nlm.nih.gov/37119513/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J06BB04;
